# Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients

> **NCT04430660** · NA · COMPLETED · sponsor: **Pennington Biomedical Research Center** · enrollment: 8 (actual)

## Conditions studied

- Diabetes
- Hypoglycemia

## Interventions

- **OTHER:** 13C-MRS procedure/Acetate infusion
- **DEVICE:** Continuous glucose monitoring

## Key facts

- **NCT ID:** NCT04430660
- **Lead sponsor:** Pennington Biomedical Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-19
- **Primary completion:** 2022-03-29
- **Final completion:** 2022-05-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430660, "Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04430660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*